BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
82.95
-1.14 (-1.36%)
Jul 15, 2026, 3:24 PM EDT - Market open
BridgeBio Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 579.96 | 502.08 | 221.9 | 9.3 | 77.65 | 69.72 | |
Revenue Growth (YoY) | 355.17% | 126.26% | 2285.27% | -88.02% | 11.38% | 745.14% |
Cost of Revenue | 28.26 | 20.96 | 3.88 | 2.45 | 3.43 | 3.11 |
Gross Profit | 551.7 | 481.11 | 218.02 | 6.86 | 74.21 | 66.6 |
Selling, General & Admin | 588.76 | 531.23 | 288.93 | 150.59 | 143.19 | 192.21 |
Research & Development | 467.16 | 451.95 | 506.46 | 455.71 | 399.46 | 451.02 |
Other Operating Expenses | 20.78 | 21.35 | 15.61 | 7.93 | 43.77 | - |
Total Operating Expenses | 1,077 | 1,005 | 811 | 614.23 | 586.42 | 643.23 |
Operating Income | -525 | -523.41 | -592.97 | -607.37 | -512.2 | -576.63 |
Interest Income | 20.72 | 19.85 | 17.25 | 18.04 | 7.54 | 1.13 |
Interest Expense | -113.83 | -178.24 | -99.29 | -81.29 | -80.44 | -46.78 |
Other Non-Operating Income (Expense) | -36.26 | -50.71 | 132.82 | 17.37 | 100.45 | 35.82 |
Total Non-Operating Income (Expense) | -204.46 | -209.09 | 50.78 | -45.88 | 27.55 | -9.82 |
Pretax Income | -562.9 | -732.5 | -542.19 | -653.25 | -484.65 | -586.45 |
Provision for Income Taxes | 0.44 | 0.44 | 1.15 | - | - | - |
Net Income | -729.89 | -732.94 | -543.35 | -653.25 | -484.65 | -586.45 |
Minority Interest in Earnings | -8.33 | -8.01 | -7.59 | -10.05 | -3.47 | -23.92 |
Net Income to Common | -721.55 | -724.93 | -535.76 | -643.2 | -481.18 | -562.54 |
Shares Outstanding (Basic) | 193 | 192 | 186 | 163 | 147 | 144 |
Shares Outstanding (Diluted) | 193 | 192 | 186 | 163 | 147 | 144 |
Shares Change (YoY) | 1.99% | 2.93% | 14.30% | 10.39% | 2.16% | 22.34% |
EPS (Basic) | -3.74 | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
EPS (Diluted) | -3.74 | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
Free Cash Flow | -445.12 | -447.01 | -521.66 | -529.03 | -424.32 | -511.18 |
Free Cash Flow Per Share | -2.31 | -2.33 | -2.80 | -3.25 | -2.88 | -3.54 |
Gross Margin | 95.13% | 95.82% | 98.25% | 73.71% | 95.58% | 95.53% |
Operating Margin | -90.52% | -104.25% | -267.22% | -6528.75% | -659.65% | -827.12% |
Profit Margin | -125.85% | -145.98% | -244.86% | -7021.94% | -624.16% | -841.20% |
FCF Margin | -76.75% | -89.03% | -235.08% | -5686.62% | -546.46% | -733.23% |
EBITDA | -519.66 | -517.98 | -586.9 | -600.88 | -505.43 | -570.79 |
EBITDA Margin | -89.60% | -103.17% | -264.49% | -6458.95% | -650.93% | -818.74% |
EBIT | -525 | -523.41 | -592.97 | -607.37 | -512.2 | -576.63 |
EBIT Margin | -90.52% | -104.25% | -267.22% | -6528.75% | -659.65% | -827.12% |
Effective Tax Rate | -0.08% | -0.06% | -0.21% | 0.00% | 0.00% | 0.00% |